✦ LIBER ✦

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

✍ Scribed by Dodel, Richard; Rominger, Axel; Bartenstein, Peter; Barkhof, Frederik; Blennow, Kaj; Förster, Stefan; Winter, Yaroslav; Bach, Jan-Philipp; Popp, Julius; Alferink, Judith; Wiltfang, Jens; Buerger, Katharina; Otto, Markus; Antuono, Piero; Jacoby, Michael; Richter, Ralph; Stevens, James; Melamed, Isaac; Goldstein, Jerome; Haag, Stefan; Wietek, Stefan; Farlow, Martin; Jessen, Frank

Book ID: 122391792
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 746 KB
Volume: 12
Category: Article
ISSN: 1474-4465
DOI: 10.1016/S1474-4422(13)70014-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled dose-finding trial of intravenous immunoglobulin (IVIG; Octagam® 10%, Octapharma AG) in patients with mild to moderate Alzheimer's disease (GAM10-04)

✍ Dodel, Richard; Rominger, Axel; Blennow, Kaj; Barkhof, Frederik; Wietek, Stefan; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 87 KB

Melissa officinalis extract in the treat

Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial

✍ Akhondzadeh, S 📂 Article 📅 2003 🏛 BMJ Publishing Group 🌐 English ⚖ 224 KB

Randomized double-blind placebo-controll

Randomized double-blind placebo-controlled dose-finding trial of intravenous immunoglobulin (octagam® 10%, octapharma AG) in patients with Alzheimer's disease

✍ Farlow, Martin R.; Jessen, Frank; Wietek, Stefan; Melsen, Tina; Haag, Stefan; Do 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Masitinib as an adjunct therapy for mild

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial

✍ François Piette, Joël Belmin, Hélène Vincent… 📂 Article 📅 2011 🏛 BioMed Central 🌐 English ⚖ 349 KB

A 22-week, multicenter, randomized, doub

A 22-week, multicenter, randomized, double-blind controlled trial ofCrocus sativusin the treatment of mild-to-moderate Alzheimer’s disease

✍ Shahin Akhondzadeh; Mehdi Shafiee Sabet; Mohammad Hossein Harirchian; Mansoreh T 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 161 KB

Study of the ketogenic agent AC-1202 in

Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial

✍ Samuel T Henderson; Janet L Vogel; Linda J Barr; Fiona Garvin; Julie J Jones; La 📂 Article 📅 2009 🏛 BioMed Central 🌐 English ⚖ 640 KB